Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. KalVista Pharmaceuticals Inc shares valued at $115,537 were sold by Palleiko Benjamin L on Sep 08 ’25. At $15.84 per share, Palleiko Benjamin L sold 7,294 shares. The insider’s holdings dropped to 395,189 shares worth approximately $5.49 million following the completion of this transaction.
Also, Sweeny Nicole sold 1,480 shares, netting a total of over 19,862 in proceeds. Following the sale of shares at $13.42 each, the insider now holds 32,291 shares.
Before that, Yea Christopher had sold 1,954 shares from its account. In a trade valued at $26,223, the CHIEF DEVELOPMENT OFFICER traded KalVista Pharmaceuticals Inc shares for $13.42 each. Upon closing the transaction, the insider’s holdings decreased to 1,954 shares, worth approximately $1.83 million.
As published in their initiating research note from JMP Securities on January 31, 2025, KalVista Pharmaceuticals Inc [KALV] has been a Mkt outperform and the price target has been revised to $19. Analysts at TD Cowen started covering the stock with ‘”a Buy”‘ outlook in a report released in early January. As of December 18, 2024, BofA Securities has initiated its “Buy” rating for KALV. Earlier on June 15, 2020, H.C. Wainwright initiated its rating. Their recommendation was “a Buy” for KALV stock.
Analyzing KALV Stock Performance
On last trading session, KalVista Pharmaceuticals Inc [NASDAQ: KALV] rose 3.74% to $13.88. The stock’s lowest price that day was $13.41, but it reached a high of $13.91 in the same session. During the last five days, there has been a drop of approximately -6.28%. Over the course of the year, KalVista Pharmaceuticals Inc shares have jumped approximately 28.88%.
Is KalVista Pharmaceuticals Inc subject to short interest?
Stocks of KalVista Pharmaceuticals Inc saw a sharp rise in short interest on 2025-08-29 jumping by 0.51 million shares to 10.56 million. Data from Yahoo Finance shows that the short interest on 2025-07-31 was 10.06 million shares. A jump of 4.79% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 15.61 of the overall float, the days-to-cover ratio (short ratio) jumped to 15.61.
Which companies own the most shares of KalVista Pharmaceuticals Inc (KALV)?
In terms of KalVista Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 20 in the next 12 months, up nearly 49.48% from the previous closing price of $13.38. Analysts anticipate KalVista Pharmaceuticals Inc stock to reach 28 by 2025, with the lowest price target being 20. In spite of this, 2 analysts ranked KalVista Pharmaceuticals Inc stock as Buy at the end of 2025. On July 29, 2019, SVB Leerink assigned a price target of “an Outperform” to the stock and initiated coverage with a $31.
